Clinverse records four partnerships, significant growth in Q1

By Zachary Brennan

- Last updated on GMT

Clinverse records four partnerships, significant growth in Q1

Related tags: Contract

CRO and sponsor payment service provider Clinverse announced a record first quarter to start 2014, with the addition of four significant new clients, as well as strong additional repeat business from existing clients.

As backlog increased by 132%, Clinverse won a 5-year agreement with a top CRO, which means Clinverse will immediately implement ClinPay across their organization and automate investigator payments for existing and future Phase 1 through Phase IV global studies. 

OmniComm and Clinverse partnered back in September​, as OmniComm combined its EDC (electronic data capture) system with Clinverse's ClinPay tool.

The implementation of the Sunshine Act​ also “has been a positive impact on our business as it is driving awareness, as well as making accurate payments a key requirement in any solution chosen by a CRO or sponsor​,” Jay Trepanier, CFO of Clinverse, told  

Our reporting capabilities and metric scorecards are very attractive because of the Sunshine Act regulation​.”

With an increase of more than 132% in backlog, we’re in an excellent position in a fast-growing industry​,” Trepanier said. “We’re gaining great traction and quickly becoming recognized as the leader in a relatively new, and rapidly growing, untapped market​.”

Strategic deals

The company, which exceeded revenue expectations by 12%, also won two strategic partnerships from a mid-size biopharma client and a global 500-site Phase III rescue study for a smaller biotech client.

In Q1 the company also upped its investments in strategic programs and will release four new additions to the ClinPay product suite this year.

This quarter has set the pace for what is expected to be a great year for Clinverse​,” said Denis Connaghan, CEO, Clinverse, Inc. “The market growth has resulted in our pipeline more than doubling over the past 9 months​.”

The future quarters also seem to have be garnering high expectations. Trepanier added that there’s a “huge upside and expectations as our Q1 results indicate​” as long term agreements have been reached with large CRO and sponsors, as well as repeat customers.  “Backlog and pipeline [are] showing substantial growth, which bodes very well for our future​," he added.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

Related suppliers

Follow us


View more